514.65
price up icon2.53%   12.70
after-market アフターアワーズ: 514.65
loading
前日終値:
$501.95
開ける:
$507.89
24時間の取引高:
1.23M
Relative Volume:
0.86
時価総額:
$130.44B
収益:
$12.34B
当期純損益:
$4.34B
株価収益率:
30.51
EPS:
16.8685
ネットキャッシュフロー:
$3.71B
1週間 パフォーマンス:
+6.07%
1か月 パフォーマンス:
+1.24%
6か月 パフォーマンス:
+17.18%
1年 パフォーマンス:
+22.80%
1日の値動き範囲:
Value
$505.00
$515.74
1週間の範囲:
Value
$487.54
$517.68
52週間の値動き範囲:
Value
$403.16
$560.25

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
名前
Vertex Pharmaceuticals Inc
Name
セクター
Healthcare (1052)
Name
電話
(617) 341-6393
Name
住所
50 NORTHERN AVENUE, BOSTON, MA
Name
職員
6,400
Name
Twitter
@VertexPharma
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
VRTX's Discussions on Twitter

Compare VRTX vs MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
514.65 130.44B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
242.08 96.65B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
807.48 83.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
869.72 54.69B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
384.50 43.50B 5.76B 514.49M 1.10B 4.4813

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-21 開始されました Leerink Partners Outperform
2026-09-02 再開されました Morgan Stanley Overweight
2026-05-27 再開されました Truist Buy
2026-03-18 アップグレード Maxim Group Hold → Buy
2026-03-10 開始されました Jefferies Buy
2026-03-10 繰り返されました Oppenheimer Outperform
2026-02-13 アップグレード Oppenheimer Perform → Outperform
2026-01-28 再開されました Barclays Overweight
2026-01-22 アップグレード RBC Capital Mkts Sector Perform → Outperform
2026-01-12 アップグレード Bernstein Mkt Perform → Outperform
2026-01-07 再開されました UBS Buy
2026-01-06 アップグレード Wolfe Research Peer Perform → Outperform
2025-12-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-11-13 開始されました Scotiabank Sector Outperform
2025-09-25 アップグレード Leerink Partners Market Perform → Outperform
2025-09-03 開始されました Raymond James Mkt Perform
2025-08-06 アップグレード Wells Fargo Equal Weight → Overweight
2025-05-07 ダウングレード Wolfe Research Outperform → Peer Perform
2025-05-06 ダウングレード Leerink Partners Outperform → Market Perform
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-02-12 アップグレード Canaccord Genuity Sell → Hold
2025-02-11 アップグレード Canaccord Genuity Sell → Hold
2025-01-30 ダウングレード Wells Fargo Overweight → Equal Weight
2024-12-20 繰り返されました H.C. Wainwright Buy
2024-12-19 ダウングレード Oppenheimer Outperform → Perform
2024-12-09 アップグレード Jefferies Hold → Buy
2024-11-14 開始されました Citigroup Buy
2024-10-16 開始されました Scotiabank Sector Perform
2024-10-10 再開されました Raymond James Mkt Perform
2024-08-05 ダウングレード Barclays Overweight → Equal Weight
2024-06-27 開始されました Redburn Atlantic Buy
2024-04-11 アップグレード Evercore ISI In-line → Outperform
2024-02-15 開始されました Wolfe Research Outperform
2024-02-06 ダウングレード Evercore ISI Outperform → In-line
2024-02-02 ダウングレード Bernstein Outperform → Mkt Perform
2024-01-31 ダウングレード Maxim Group Buy → Hold
2024-01-31 ダウングレード Robert W. Baird Neutral → Underperform
2024-01-24 ダウングレード Canaccord Genuity Hold → Sell
2023-12-14 繰り返されました RBC Capital Mkts Sector Perform
2023-05-30 開始されました William Blair Outperform
2023-05-04 再開されました Piper Sandler Overweight
2023-03-21 開始されました Bernstein Outperform
2023-01-18 開始されました Canaccord Genuity Hold
2023-01-17 アップグレード SVB Leerink Mkt Perform → Outperform
2022-12-19 ダウングレード Jefferies Buy → Hold
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-01 アップグレード Maxim Group Hold → Buy
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-05-06 ダウングレード Robert W. Baird Outperform → Neutral
2022-05-03 アップグレード Morgan Stanley Underweight → Equal-Weight
2022-02-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-01-27 繰り返されました JP Morgan Overweight
2022-01-27 繰り返されました Morgan Stanley Underweight
2022-01-27 繰り返されました RBC Capital Mkts Outperform
2022-01-27 繰り返されました Stifel Hold
2022-01-27 繰り返されました Wolfe Research Outperform
2022-01-20 アップグレード BMO Capital Markets Market Perform → Outperform
2021-12-09 開始されました Wells Fargo Overweight
2021-11-19 開始されました BMO Capital Markets Market Perform
2021-11-19 ダウングレード Piper Sandler Overweight → Neutral
2021-09-09 ダウングレード Stifel Buy → Hold
2021-09-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-07-20 ダウングレード SVB Leerink Mkt Perform → Underperform
2021-07-19 再開されました Wolfe Research Outperform
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-11 ダウングレード Daiwa Securities Outperform → Neutral
2021-02-23 アップグレード Robert W. Baird Neutral → Outperform
2021-02-02 繰り返されました H.C. Wainwright Buy
2020-12-30 開始されました Daiwa Securities Outperform
2020-11-30 アップグレード RBC Capital Mkts Sector Perform → Outperform
2020-11-20 開始されました Bernstein Outperform
2020-10-28 開始されました UBS Buy
2020-07-31 繰り返されました H.C. Wainwright Buy
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-04-30 繰り返されました H.C. Wainwright Buy
2020-04-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-03-04 開始されました Barclays Overweight
2020-01-31 ダウングレード Robert W. Baird Outperform → Neutral
2019-11-19 アップグレード Guggenheim Neutral → Buy
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-09-03 アップグレード Goldman Neutral → Buy
2019-08-01 ダウングレード Needham Buy → Hold
2019-05-23 再開されました Citigroup Buy
2019-05-21 開始されました Credit Suisse Outperform
2019-04-12 開始されました Evercore ISI In-line
2019-03-26 アップグレード William Blair Mkt Perform → Outperform
2019-03-19 ダウングレード SVB Leerink Outperform → Mkt Perform
2019-02-06 ダウングレード Maxim Group Buy → Hold
すべてを表示

Vertex Pharmaceuticals Inc (VRTX) 最新ニュース

pulisher
07:55 AM

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

07:55 AM
pulisher
Oct 19, 2026

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It - The Motley Fool

Oct 19, 2026
pulisher
Oct 18, 2026

Where Will CRISPR Therapeutics Stock Be in 2030? - The Motley Fool

Oct 18, 2026
pulisher
Oct 18, 2026

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. - The Motley Fool

Oct 18, 2026
pulisher
Oct 16, 2026

Meridian International Center Unveils Inaugural New Architects of American Influence Cohort - GlobeNewswire Inc.

Oct 16, 2026
pulisher
Oct 16, 2026

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Zacks Investment Research

Oct 16, 2026
pulisher
Oct 15, 2026

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders - The Motley Fool

Oct 15, 2026
pulisher
Oct 13, 2026

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Oct 13, 2026
pulisher
Oct 11, 2026

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool

Oct 11, 2026
pulisher
Oct 09, 2026

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

Is Vertex Stock Worth More Than Its Competitors? - Trefis

Oct 09, 2026
pulisher
Oct 09, 2026

If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga

Oct 09, 2026
pulisher
Oct 09, 2026

RBC raises target for Vertex Pharma stock from USD 570 to USD 576 - AD HOC NEWS

Oct 09, 2026
pulisher
Oct 08, 2026

RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating - www.marketscreener.com

Oct 08, 2026
pulisher
Oct 07, 2026

Vertex to Announce Third Quarter 2026 Financial Results November 2nd - Business Wire

Oct 07, 2026
pulisher
Oct 06, 2026

Vertex Pharmaceuticals Incorpor (VRTX) Stock forecasts - Yahoo Finance UK

Oct 06, 2026
pulisher
Oct 06, 2026

Vertex Pharma stock after-hours at EUR 446.63: minus 0.62 percent versus prior close - AD HOC NEWS

Oct 06, 2026
pulisher
Oct 06, 2026

Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 05, 2026

Healthcare Sector Highlights 16 A+ Growth Stocks Including Verte - GuruFocus

Oct 05, 2026
pulisher
Oct 05, 2026

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Oct 05, 2026
pulisher
Oct 04, 2026

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool

Oct 04, 2026
pulisher
Oct 02, 2026

Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets - Yahoo Finance

Oct 02, 2026
pulisher
Oct 01, 2026

Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks - Yahoo Finance

Oct 01, 2026
pulisher
Oct 01, 2026

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Zacks Investment Research

Oct 01, 2026
pulisher
Oct 01, 2026

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance

Oct 01, 2026
pulisher
Oct 01, 2026

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 01, 2026
pulisher
Oct 01, 2026

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey

Oct 01, 2026
pulisher
Oct 01, 2026

M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy - BioSpace

Oct 01, 2026
pulisher
Sep 29, 2026

$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga

Sep 29, 2026
pulisher
Sep 29, 2026

Vertex Pharmaceuticals- Still Too Much Emphasis On CF SupremacyI Foresee A Downgrade - Seeking Alpha

Sep 29, 2026
pulisher
Sep 29, 2026

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - The Motley Fool

Sep 29, 2026
pulisher
Sep 29, 2026

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating - Moomoo

Sep 29, 2026
pulisher
Sep 29, 2026

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - Yahoo Finance

Sep 29, 2026
pulisher
Sep 28, 2026

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance

Sep 28, 2026
pulisher
Sep 28, 2026

Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance

Sep 28, 2026
pulisher
Sep 27, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 27, 2026
pulisher
Sep 24, 2026

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 24, 2026
pulisher
Sep 24, 2026

BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV) - The Globe and Mail

Sep 24, 2026
pulisher
Sep 23, 2026

Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

Vertex Pharma options analysis: heavy put activity signals near-term caution - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research

Sep 23, 2026
pulisher
Sep 23, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript - fortune.com

Sep 23, 2026
pulisher
Sep 22, 2026

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool

Sep 22, 2026
pulisher
Sep 22, 2026

The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily

Sep 22, 2026

Vertex Pharmaceuticals Inc (VRTX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Vertex Pharmaceuticals Inc (VRTX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
Jul 02 '26
Sale
524.99
1,500
787,485
45,321
McKechnie Duncan
EVP, Chief Commercial Officer
Jul 02 '26
Sale
519.00
1,541
799,779
11,001
Tatsis Ourania
Officer
Jul 02 '26
Proposed Sale
524.99
1,500
787,485
0
McKechnie Duncan
Officer
Jul 02 '26
Proposed Sale
519.00
1,541
799,779
0
Liu Joy
EVP and Chief Legal Officer
Jul 01 '26
Sale
502.71
828
416,244
19,131
Liu Joy
Officer
Jul 01 '26
Proposed Sale
502.71
828
416,244
0
Bozic Carmen
EVP and CMO
Jun 26 '26
Sale
482.50
596
287,570
15,337
Bozic Carmen
Officer
Jun 26 '26
Proposed Sale
482.50
596
287,570
0
Bozic Carmen
Officer
Jun 18 '26
Proposed Sale
462.17
1,020
471,413
0
Bozic Carmen
EVP and CMO
Jun 18 '26
Sale
462.17
1,020
471,413
15,933
$242.08
price up icon 6.69%
$807.48
price up icon 3.25%
$869.72
price up icon 5.34%
ONC ONC
$384.50
price up icon 3.87%
$196.55
price up icon 7.91%
$230.71
price down icon 1.11%
大文字化:     |  ボリューム (24 時間):